AiCure is an AI and advanced data analytics company targeting the healthcare industry. Our proprietary intelligent software captures and understands video, audio, and behavioral data to establish the link between patients, disease and treatment.

Validated to be accurate and to modify behavior

Applications in drug development and population health

A patented artificial intelligence foundation

Developing new paradigms to understand treatment response.

Built on a foundation of longitudinal patient data

Accurate confirmation of medication ingestion

Validated against plasma blood levels

Behavior modification

20% - 60% improvements according to blood levels

Rich data fuels predictive insights

Over 1 Million behavioral interactions with IMA

Reduces medical costs for payors
Reduces trial failure for pharma companies
See our peer-reviewed publications

In drug development, we are defining new methodologies and enrichment strategies

Clear value is essential in understanding the application of new technology. AiCure’s value is structured around four key pillars: data integrity; lower variability; predictive composite measures; and increases in statistical power. Incorporating these data pillars into study design allows for faster, smaller trials. AiCure is also demonstrating significant results by introducing new trial methodologies such as placebo lead-in periods, micro-reimbursements, and other approaches directly correlated with patient engagement and clinical endpoints.

Test tube

For payors, we are reducing medical costs and waste Medication

adherence is one of the few parameters in healthcare that is directly linked to medical costs. AiCure has demonstrated significant savings for some of the largest payors and states by ensuring high-risk patient populations stay on therapy.

Fingerprint reader

For science and the healthcare industry, we are developing novel clinical endpoints through computational diagnostics

AiCure is pioneering a new set of tools to help researchers and clinicians understand and predict how patients respond to treatment. Advances in artificial intelligence allow computers to capture physiological datapoints that characterize expressivity, psychomotor function, and cognition. Whether a patient has schizophrenia or congestive heart failure, the degree to which they are able to adhere and respond to treatment depends in great part on their mood, their ability to move and to concentrate. AiCure is leading a multi-stakeholder R&D effort with industry and academia to develop these transdiagnostic domains and novel sensitive endpoints.

Computational diagnosis

AiCure News

December 18, 2018

Building a High-Tech, High-Touch Model for Drug Management

Caroline Carney, MD, MSc Caroline Carney, MD, MSc, is the chief medical officer for Magellan Rx Management, the pharmacy…

December 12, 2018

AiCure’s client base sees uptick as the industry looks to reduce risk

AiCure’s client base sees uptick as the industry looks to reduce risk By Maggie Lynch December 12,…

December 3, 2018

AiCure's Revenue Soars as it Bolsters Client List and Executive Team

NEW YORK, Dec. 3, 2018 /PRNewswire/ — AiCure, a behavioral data analytics company targeting the healthcare…

November 30, 2018

An Insight Of AI’s Penetration In Drug Development Market

Yiannis Mouratidis – Contributor, Science Different universes converge in the path of AI-based drug developmentDEEP KNOWLEDGE VENTURES A recent article about…

November 1, 2018

5 Q’s for Adam Hanina, CEO of AiCure

The Center for Data Innovation spoke with Adam Hanina, chief executive officer of AiCure, a healthcare software company based in…

December 14, 2017

AiCure Named to the 2018 AI 100, Highlighting Advancements in Artificial Intelligence for Patient Monitoring

SAN FRANCISCO, Dec. 12, 2017 /PRNewswire/ — CB Insights today named AiCure to the prestigious …

Investors

Intellectual property - Over 100 patents filed

Treatment Observation

Advanced Interaction

AI Methodologies

Computational DX

Fraud Detection

Next-Gen Labeling

Analytics

Other